Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Korro Bio ( (KRRO) ) just unveiled an announcement.
On October 7, 2025, Vineet Agarwal announced his resignation as Chief Financial Officer of Korro Bio, effective October 17, 2025, to pursue another opportunity. He will serve as an advisor for 30 days post-resignation to ensure a smooth transition. His departure is amicable and not due to any disagreements with the company. Korro Bio’s board has appointed Dr. Ram Aiyar, the current President and CEO, as interim CFO effective October 17, 2025, without additional compensation. This transition is aimed at maintaining stability within the company’s financial operations.
The most recent analyst rating on (KRRO) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.
Spark’s Take on KRRO Stock
According to Spark, TipRanks’ AI Analyst, KRRO is a Neutral.
Korro Bio’s stock score reflects its current position as a developmental biotech firm. Financial performance is the most significant factor, showing the challenges of high R&D costs and reliance on external funding. The technical analysis suggests short-term downward pressure, while valuation is impacted by its negative earnings and lack of dividends. The company needs to focus on operational efficiency and revenue growth to improve its stock performance.
To see Spark’s full report on KRRO stock, click here.
More about Korro Bio
Average Trading Volume: 194,338
Technical Sentiment Signal: Buy
Current Market Cap: $410.4M
For an in-depth examination of KRRO stock, go to TipRanks’ Overview page.